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Abstract
Background—Exposure to antenatal corticosteroids (ANCS) is associated with adverse cardio-
metabolic outcomes in animal models; however long-term outcomes in clinical studies are not well 
characterized. We hypothesized that exposure to ANCS would be associated with markers of 
increased cardio-metabolic risk in adolescents born with very low birth weight (VLBW).
Methods—In an observational cohort of 186 VLBW 14-year-old adolescents we measured 
resting blood pressure (BP), BP response to cold, ambulatory BP, and anthropometrics; performed 
dual-energy X-ray absorptiometry; and analyzed blood samples for uric acid, cholesterol, glycated 
hemoglobin, and high-sensitivity C-reactive protein. Multivariate analyses were used to evaluate 
associations with ANCS, adjusting for race, sex, and maternal hypertensive pregnancy.
Results—There were no ANCS group differences in BP measures or blood biomarkers. 
Compared to adolescents unexposed to ANCS, those exposed to ANCS were taller [exposed-
unexposed mean difference 3.1 cm (95% CI 0.7, 5.5)] and had decreased waist-to-height ratio 
[exposed-unexposed mean difference −0.03 (95% CI −0.058, −0.002)]. Males exposed to ANCS 
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had lower total cholesterol [exposed-unexposed mean difference −0.54 mmol/L (95%CI −0.83, 
−0.06)].
Conclusion—Among adolescents born with VLBW, ANCS exposure was not associated with 
markers of increased cardio-metabolic risk.
INTRODUCTION
In the United States (US), treatment with corticosteroids has been recommended since 1994 
for pregnant women expected to deliver prior to 34 weeks to reduce mortality and morbidity 
in the offspring.(1,2) Preclinical studies of antenatal corticosteroid (ANCS) treatment have 
raised concerns about long-term adverse effects of ANCS on blood pressure (BP) and 
cardio-metabolic risk in the offspring.(3–6) Clinical studies have not detected associations of 
ANCS with overt cardio-metabolic disease,(7,8) other than possible alterations in BP, 
vascular stiffness, and glucose metabolism.(9–11) In the largest follow-up study of patients 
from a randomized controlled trial of ANCS, the mean gestational age at birth was 34 
weeks.(11) Information about ANCS effects at earlier gestational ages is limited to studies 
with small sample sizes and/or limited racial diversity. Additionally, cohorts with follow-up 
into adolescence or adulthood were born in the late 1960s to early 1980s.
Currently, almost all very low birth weight (VLBW) infants born in the US are exposed to 
ANCS, and care has evolved such that fetuses are exposed to ANCS at earlier gestational 
ages. Contemporary survivors of preterm birth are maturing in the epidemic of obesity, 
potentially exposing them to a “second hit” that might potentiate putative programming 
effects of ANCS.(12) Thus, we recruited a racially diverse and contemporary cohort of 
adolescents born prematurely with VLBW, to study the effects of ANCS exposure on BP 
and cardio-metabolic risk factors.
METHODS
Study design
The study sample was derived from a cohort of consecutive VLBW singleton births at the 
regional perinatal center in Forsyth County, North Carolina from January 1, 1992 to June 30, 
1996 who had no major congenital malformations and returned for evaluation at one year 
adjusted age. Figure 1 describes the cohort’s participation in the follow-up study. We 
estimated that a total sample of 158 (79 in each ANCS group) would be needed to provide 
90% statistical power to detect a between-group difference in the primary outcome, resting 
auscultatory systolic BP (SBP), of 4 mmHg (alpha = 0.05, two-sided testing). The 4 mmHg 
difference used for determining sample size is the difference reported by Doyle et al. in a 
study of VLBW individuals.(9) As ANCS exposure was determined post-enrollment, the 
study sample exceeded our target due to continuous accrual of participants. This study was 
approved by the Wake Forest School of Medicine and the Forsyth Medical Center 
Institutional Review Boards. Informed consent was obtained from parents or legal guardians, 
and participants gave assent.
Information about the pregnancy including ANCS exposure (betamethasone and/or 
dexamethasone), maternal hypertension during pregnancy, and type of delivery was obtained 
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by review of medical records or from research databases. We excluded two participants 
whose mothers were treated with steroids during pregnancy for other medical conditions.
To estimate gestational age, we used, in order of priority, a first trimester ultrasound, the 
mother’s last menstrual period, or clinical assessment of the neonate. As an index of fetal 
growth, we used birth weight z-score, calculated using US natality data.(13) Birth weight 
and postnatal dexamethasone treatment to prevent BPD (defined as use of supplemental 
oxygen at 36 weeks corrected gestational age) were obtained from review of the 
participants’ medical record. As potential indicators of perinatal social economic status we 
used mother’s marital status (married or non-married) and education status (≤ 12 years or > 
12 years), and at age 14 years, we used Medicaid health insurance. Participant’s race was 
categorized as black or non-black, based on parent or guardian report at the 14-year visit. Z-
scores and percentiles for measurements made at 14 years were derived using Epi Info™ 
(Centers for Disease Control, Atlanta, Georgia).(14) We categorized BMI ≥85th percentile as 
overweight/obese.(15) Pubertal maturation status was assessed in private using self-
completed questionnaires based on Tanner staging for pubic hair, breast development in 
females, and genital development in males.(16) Family history of cardiovascular disease was 
determined by parent or guardian report of maternal or paternal hypertension, stroke, or 
heart attack. Current medication use was reported by a parent or guardian and the 
participants.
Participants were seen for three visits during their 15th year of life. The ½ day visits were 
performed in a General Clinical Research Center. Participants were asked to refrain from 
caffeine containing beverages for 24 hours prior to the visit. At each visit, BP was measured 
in the right arm with a mercury sphygmomanometer by nursing staff certified in BP 
measurement using guidelines established by the National High Blood Pressure Education 
Program Working Group on Hypertension Control in Children and Adolescents.(17) Proper 
cuff size was determined using mid-upper arm circumference. Participants were seated 
quietly for 5 minutes with the back supported, the forearm at heart level, and feet flat on the 
floor. The average of three measurements was used to estimate SBP and diastolic BP (DBP). 
The average of five resting oscillometric BP measurements were recorded using the same 
procedure with the Dinamap® Pro 100 (Critikon).(18)
The BP response to forehead cold stimulation was performed at the first visit following the 
procedures of Dysart et al.(19) During the 11th, 13th, and 15th minute of rest, baseline BP 
measurements were made using the Dinamap® Pro 100 (Critikon). A bag of ice water was 
placed on the subject’s forehead for one minute. At the end of the minute, BP was measured, 
and the bag was removed. The difference between the peak BP and the average of the three 
baseline BP measures was calculated.
Ambulatory BP monitoring (AMBP) was utilized in the non-dominant arm after the third 
visit (Spacelabs 90207, Redmond, WA). Participants were asked to wear the monitor for 24 
hours and keep a diary of their activities. The monitors were programmed to inflate every 20 
minutes from 7 am to 9 p.m. and every 30 minutes from 9 p.m. to 7 a.m. Studies with at least 
70% successful readings and at least one reading every hour were analyzed. The mean of 
successful daytime and nighttime readings was calculated using self-reported sleep and 
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awake times, and percentages of nocturnal SBP and DBP decline were determined. BP load 
was defined as the proportion of measurements above the 95th percentile for age, sex, and 
height.(20)
In participants willing to undergo venipuncture, a non-fasting sample of blood was obtained 
at the third visit. Total and HDL cholesterol and uric acid were determined enzymatically 
and ELISA (ALPCO, Windham, NH) was used to measure high sensitivity C-reactive 
protein (hs-CRP). Glycated hemoglobin was determined using Roche Tina-quant® assay.
Measurements of height (to the nearest hundredth of a centimeter using a wall-mounted 
stadiometer) and weight (to the nearest tenth of a kilogram using a digital platform scale) 
were made at each study visit in triplicate with participants wearing light clothing and no 
shoes. The averages of each measurement were used for analysis. At the third visit, a 
nutritionist measured waist circumference (to the nearest tenth of a centimeter with a 
measuring tape according to procedures of National Health and Nutrition Examination 
Survey III)(21) and triceps and subscapular skin fold thicknesses (using a Lange skinfold 
caliper).(22) Fat mass, fat free mass, and bone mineral content were assessed using a Delphi 
dual-energy X-ray absorptiometer (DXA) (Hologic, Bedford, MA) equipped with pediatric 
software. Lean body mass was calculated by subtracting bone mineral content from total fat 
free mass.
Statistical Analysis
Characteristics were compared using two-sample t and Fisher’s Exact tests between ANCS 
exposed and unexposed study participants and between eligible VLBW patients who were 
enrolled and not enrolled in the study. Outcome measures that were not approximately 
normally distributed were transformed prior to analysis using logarithmic or square root 
transformation as indicated. To adjust for potential confounding and other variables, multiple 
regression modeling approaches were used, including general linear regression for 
continuous outcomes and logistic regression for dichotomous outcomes. Outcomes that were 
measured across multiple participant visits were modeled based on a general linear 
regression as well, but with a random effect to portray individual differences, and with a 
first-order autocorrelation structure for the repeated measures within participants across 
visits. Covariate selection was based on prior reported relationships in the literature, 
including an ANCS x BMI interaction term, which was included in models for BP measured 
at rest and in response to cold. The modeling procedures were repeated after stratifying 
separately by sex and by race. In an effort to differentiate the effect of race and 
socioeconomic status on ANCS group differences, analyses suggesting ANCS group 
differences when stratified by race were repeated stratifying by maternal marital status. To 
allow comparison with results reported by Doyle et al, we estimated the exposed-unexposed 
mean difference in SBP, adjusting for current weight, among non-black participants.(9) 
Least squares means between ANCS-exposed and unexposed groups and adjusted odds 
ratios were used together with their corresponding 95% confidence intervals to evaluate 
associations with ANCS exposure. P values ≤0.05 were considered statistically significant. 
No correction for multiple testing was applied to outcomes, as those selected for analysis 
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were related and were used to evaluate consistency across findings. All analyses were 
performed using SAS for Windows version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Compared to those eligible but not included, the 186 participants included in the study had 
lower gestational age (mean ± SD 27.7 ± 2.6 v 28.3 ± 2.5 weeks) and higher birth weight z-
score (−0.26 ± 0.81 versus −0.43 ± 0.81) but were similar in birth weight, race, sex, and 
mode of delivery (results not shown). Participant characteristics are shown in Table 1.
For the 65 participants for whom complete data on ANCS exposure were available, all were 
exposed to betamethasone except one who received one dose each of betamethasone and 
dexamethasone, and one who received only dexamethasone. Of those exposed to multiple 
courses (two doses of betamethasone separated by one week), five received two courses, and 
two received three courses. Caesarean delivery and maternal hypertension during pregnancy 
were more common in those exposed to ANCS. Non-married mothers, mothers with less 
than or equal to high school education, and mothers of black participants were less likely to 
be exposed to ANCS (Table 1). Race was related to maternal marital status (p<0.0001) but 
not maternal education (p=0.21).
At 14 years of age, 186 (94 exposed) participants completed one visit, 179 (92 exposed) 
completed two visits, and 174 (92 exposed) completed all three study visits. There were no 
group differences in the BP outcomes as shown in Table 2. Exclusion of participants treated 
with postnatal dexamethasone to prevent BPD did not alter the results (data not shown). 
Similarly, exclusion of BP measurements potentially affected by stimulant medications for 
attention deficit hyperactivity disorder did not affect the results. Although waist-to-height 
ratio (WHtR) at 14 years was positively correlated with auscultatory and oscillometric SBP 
(r=0.25 and r=0.34, respectively, p<0.001), we did not detect significant ANCS x BMI 
interactions. When stratified by sex, ANCS-exposed females had higher resting auscultatory 
DBP (63.2 ± 0.9 v 60.7± 0.9 mmHg; p=0.072) which was attenuated when adjusted for race, 
height, and maternal hypertensive pregnancy. When stratified by race, ANCS-exposed non-
black participants had higher auscultatory SBP (106.0 ± 1.1 v 102.6 ± 1.4 mmHg; p=0.063), 
DBP (61.5 ± 0.9 v 58.6 ± 1.2 mmHg; p=0.065) and higher peak SBP response to cold stress 
(128.5 ±12.6 v 123.6 ± 10.8 mmHg; p=0.051). The ANCS group differences in non-blacks 
were attenuated when adjusted for sex, height, and maternal hypertensive pregnancy. 
However, resting auscultatory SBP was higher in ANCS exposed non-blacks when current 
BMI replaced height in the model [exposed-unexposed mean difference 3 mmHg (95% CI 
0.07, 6.9, p=0.045)]. In contrast to results stratified by race, there were no ANCS group 
differences in BP outcomes when stratified by maternal marital status.
There were also no ANCS group differences in circulating biomarkers (Table 3). However, 
among males, ANCS exposure was associated with lower total cholesterol [exposed-
unexposed mean difference −0.54 mmol/L (95% CI −0.83, −0.06), p= 0.029] when adjusted 
for race and hypertensive pregnancy. This relationship was attenuated when adjusted for 
central adiposity (WHtR) [exposed-unexposed mean difference −0.14 mmol/L (95% CI 
−0.57, 0.28), p= 0.52].
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Anthropometric measures of the participants at 14 years of age are shown in Table 4. 
Participants exposed to ANCS were taller, had a lower WHtR and tended to have a lower 
sum of triceps and subscapular skinfold thicknesses. There were no ANCS group differences 
in body composition variables obtained by DXA. Three percent of each group were 
classified as underweight (BMI <5th percentile) and about one-third of each group (29% 
exposed, 37% unexposed; p=0.27) were classified as overweight (BMI ≥ 85th percentile). In 
subgroup analyses, the ANCS group differences in the sum of triceps and subscapular 
skinfold thicknesses were greater in non-blacks [exposed –unexposed mean difference, −8.7 
mm (95% CI −15.2, −2.2), p=0.009] than blacks [exposed –unexposed mean difference, 1.3 
mm (95% CI −7.4, 10.1), p=0.76] adjusted for sex and hypertensive pregnancy, and in males 
[exposed –unexposed mean difference, −7.5 mm (95% CI −15.1, 0.2), p=0.056] compared to 
females [exposed –unexposed mean difference, −0.9 mm (95% CI −8.2, 6.4), p=0.80], 
adjusted for race and hypertensive pregnancy. In contrast to results stratified by race, there 
were no ANCS group differences in skin fold thicknesses when stratified by maternal 
marital status.
DISCUSSION
In a cohort of adolescents born with VLBW, we found no associations between exposure to 
ANCS and measures of resting BP, ambulatory BP monitoring (ABPM), or BP response to 
cold stress, total or HDL cholesterol, HbA1c, or uric acid. Exposure to ANCS was associated 
with increased height and decreased WHtR at 14 years of age. Among males, exposure to 
ANCS was associated with lower total cholesterol and among non-blacks, ANCS was 
associated with a lower sum of triceps and subscapular skinfold thickness.
Except for racial diversity, and birth years, our study cohort is similar in birth weight, 
gestational age, and age at follow-up to that studied by Doyle et al. in which the ANCS 
group had 4 mmHg higher SBP at age 14 years.(9) In the only other study to describe an 
association between ANCS and BP during adolescence, SBP was 3–4 mmHg lower among 
those exposed to ANCS.(7) Like Doyle et al. we found a positive association between SBP 
and adiposity at age 14 years and when we adjusted for current adiposity (Doyle et al 
adjusted for current weight z score), we found that among non-blacks, those exposed to 
ANCS had higher SBP.(9) We also assessed the BP response to cold stress as a potential 
indicator of future BP and found no ANCS group difference.(23,24)
Kelly et al. reported an association between ANCS and increased vascular stiffness in the 
aortic arch in young adults, despite there being no difference in peripheral BP.(10) Similarly, 
we have described physiological (lower heart rate variability) and biochemical [increased 
ratio of urinary angiotensin II to angiotensin-(1–7)] changes that could predispose ANCS-
exposed adolescents to higher BP. (25,26) Given these findings and the knowledge that 
programmed changes in BP amplify with age, differences in BP may emerge as our cohort 
ages.(27)
In agreement with Doyle et al., we found that VLBW adolescents exposed to ANCS were 
taller than their unexposed peers.(9) No studies have described decreased adiposity in those 
exposed to ANCS. In contrast, Finken et al. described an association of ANCS exposure and 
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increased abdominal adiposity in young adults who had glucocorticoid receptor gene variant 
363S.(28) Likewise, preclinical models suggest ANCS may be associated with increased 
adiposity.(5) Our finding of decreased WHtR is driven by the increased height in the 
exposed group; however, there are trends for lower sum of triceps and subscapular skinfold 
thicknesses in the ANCS-exposed group as well. It is possible that ANCS group differences 
in height might be attributable to subtle differences in puberty that our self-assessment tool 
was not sensitive enough to detect; however, other studies have not found ANCS-associated 
differences in sexual maturity.(7,9) It is also possible that chronic illness might contribute to 
decreased height, however we have previously reported ANCS was not associated with 
improved lung function at 14 years in this cohort.(29) Mathai et al. reported increased 
truncal fat in adults (especially males) who were born preterm to mothers who participated 
in the Auckland Steroid Trial.(30) Although ANCS-associated effects on anthropometry 
were not found in follow up of the Auckland Trial,(11) it is possible that exposure to 
antenatal steroids at an earlier gestational age attenuates this presumed effect of prematurity. 
Our finding of an ANCS-associated decrease in adiposity in non-blacks might be explained 
by epigenetic and/or genetic variations in the response to ANCS. We have described racial 
differences in ANCS-associated changes in heart rate variability, and Myazek et al described 
racial differences in the programming effects of low birth weight on cardiovascular risk 
factors at 7–21 years of age.(25,31)
Consistent with prior studies of the relationship between biomarkers of adverse 
cardiovascular risk and ANCS, we did not detect ANCS group differences in total or HDL 
cholesterol levels, except among males, in whom ANCS was associated with lower total 
cholesterol.(8,10,11) We did not find any ANCS-associated differences in hs-CRP or serum 
uric acid. Others have described ANCS-associated alterations in glucose metabolism, both 
increased and decreased insulin resistance, and decreased beta cell function.(8,10,11) It is 
possible that our measure of HbA1c, a marker of elevated glucose in the prior three months, 
might not have been sensitive enough to detect abnormalities in insulin sensitivity.
Our finding that black mothers were less likely to be treated with ANCS has been described 
by others.(32) Analyses to determine if an indicator of socioeconomic status, maternal 
marital status, explained the ANCS group differences we describe among non-blacks 
revealed that race does convey different information than marital status. We acknowledge 
that race provides information about multiple factors including biological and 
socioeconomic. Racial differences in socioeconomic status are well described; however, 
multiple factors such as exposure to adversity over the life course, non-equivalence of 
socioeconomic indicators across races, racism, and increased exposure to psychological 
stressors suggest that race influences health outcomes in addition to socioeconomic status.
(33)
Our study is limited by its observational design and potential for selection bias; however, 
randomized trials of ANCS treatment and placebo are no longer ethical. Strengths of our 
study include multiple measurements of BP using both the auscultatory and oscillometric 
methods on three different days; measurement of several physiological and molecular 
markers related to regulation of BP; and the inclusion of a multiracial contemporary cohort. 
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As exposure to ANCS is increasing and occurring at earlier gestational ages, continued 
study of the long term effects of ANCS on cardiovascular health is warranted.
Conclusion
ANCS exposure was not associated with higher BP or adverse cardio-metabolic risk but was 
associated with increased height and decreased adiposity in 14-year-olds born with VLBW.
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Figure 1. 
Eligibility, enrollment, and follow up of the study population.
VLBW- very low birth weight, ANCS- antenatal corticosteroid exposure, DXA- dual-energy 
X-ray absorptiometry, ABPM-ambulatory blood pressure monitoring
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Table 1
Characteristics of participants [mean ± SD or count (%)].
ANCS+
N=94
ANCS−
N=92
P value a
Perinatal
Gestational age, wks 27.7 ± 2.3 27.7 ± 2.9 0.93
Birth weight, g 1029 ± 268 1054 ± 265 0.52
Birth weight z score −0.34 ± 0.74 −0.21 ± 0.91 0.28
SGA 7 (7) 12 (13) 0.23
Cesarean delivery 55 (59) 39 (42) 0.040
Hypertensive pregnancy 40 (43) 26 (28) 0.047
Male 45 (48) 39 (42) 0.47
Black 27 (29) 51 (55) 0.0003
Dexamethasone for BPD b 22 (23) 12 (13) 0.088
BPD 23 (25) 25 (27) 0.73
Maternal education ≤12 years 43/91(47) 53/78 (68) 0.008
Non-married mother 29 (31) 53 (58) 0.0004
Age 14 years
Tanner genitalia/breast ≥4c 75 (81) 71 (80) 1.0
Tanner pubic hair ≥4c 87 (94) 79 (89) 0.30
Family history CV disease 49 (52) 51 (55) 0.66
Medicaidd 35 (38) 43 (49) 0.18
Stimulant medication 11 (12) 8 (9) 0.63
aP value for comparison between ANCS groups based on two-sample t or Fisher’s Exact test
b
n=91 ANCS−
c
n=93 ANSC+, n=89 ANCS−
d
n=91 ANCS+, n=88 ANCS−
ANCS-antenatal corticosteroid, SGA-small for gestational age, BPD-bronchopulmonary dysplasia, CV-cardiovascular
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Table 2
Blood pressure measurements at 14 years of age [mean ± SD or count (%)].
ANCS+ ANCS− Unadjusted
P value a
Adjusted Mean Difference b [or Odds Ratio where noted] 
(95%CI)
P value
Resting BP c N=94 N=92
Auscultatory SBP, mmHg 105.5 ± 0.9 104.4 ± 0.9 0.38 0.4 (−2.3, 3.1)p=0.77
Auscultatory DBP, mmHg 61.7 ± 0.7 60.1 ± 0.7 0.13 2.0 (−0.2, 4.2)p=0.080
Oscillometric SBP, mmHg 108.9 ± 0.9 108.4 ± 0.9 0.71 −0.7 (−3.3, 2.0)p=0.62
Oscillometric DBP, mmHg 59.8 ± 0.6 60.1 ± 0.6 0.65 −0.1 (−1.8, 1.6)p=0.90
BP response to cold N=92 N=87
SBP delta, mmHg 14.6 ± 9.7 14.2 ± 10.7 0.76 0.2 (−3.0, 3.4)p=0.91
DBP delta, mmHg 6.9 ± 6.7 7.9 ± 7.0 0.31 −0.7 (−2.8, 1.5)p=0.55
Ambulatory BP N=48 N=34
24 hour SBP, mmHg 115.7 ± 7.1 114.8 ± 7.1 0.57 0.6 (−2.9, 4.0)p=0.75
24 hour DBP, mmHg 65.8 ± 5.1 64.6 ± 6.2 0.34 2.1 (−0.6, 4.8)p=0.13
SBP load, % d 12.3 ± 11.0 11.9 ± 9.7 0.98 0.14 (−0.67, 0.94),
e
p=0.73
DBP load, % d 11.3 ± 8.8 9.6 ± 7.7 0.27 0.40 (−0.24, 1.06)
e
p=0.21
Nocturnal SBP dip <10% f 22 (54) 15 (50) 0.81 2.1 (0.6, 6.8)
g
p=0.22
Nocturnal DBP dip <10% f 7 (17) 2 (7) 0.29 4.0 (0.6, 28.5) 
g
p=0.16
aP value for comparison between ANCS groups based on two-sample t or Fisher exact test
b
Exposed – unexposed adjusted for race, hypertensive pregnancy, sex, and height
c
Mean ± standard error of the mean
d
Load-proportion of measurements above the 95th percentile for age, sex, height; Square root transformed for p value calculation
e
Exposed – unexposed adjusted for race and hypertensive pregnancy
f
n=41 ANCS+, n= 30 ANCS−
gOdds-ratio- adjusted for race, hypertensive pregnancy, and sex
ANCS-antenatal corticosteroid, BP-blood pressure, SBP-systolic blood pressure, DBP- diastolic blood pressure, delta=BPpeak-BPbaseline,
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Table 3
Biomarkers at 14 years of age [mean ± SD].
ANCS+
n=73
ANCS−
n=50
Unadjusted
p value a
Adjusted Mean Difference b (95%CI)
P value
Hs-CRP, nmol/L 1.42 ± 3.14 1.32 ± 1.91 0.85 0.04 (−1.02, 1.10)p=0.94
Uric acid, μmol/L 313.5 ± 76.1 311.7 ± 73.2 0.90 −19.2 (−43.1, 4.8)p=0.11
Total cholesterol, mmol/L 3.91 ± 0.79 4.18 ± 0.92 0.086 −0.29 (−0.62, 0.04)p=0.084
HDL cholesterol, mmol/L 1.22 ± 0.37 1.29 ± 0.32 0.26 0.0 (−0.13, 0.13)p=0.98
HbA1C, % 5.45 ± 0.31 5.43 ± 0.36 0.82 0.04 (−0.08, 0.16)p=0.50
aP value for comparison between ANCS groups based on two-sample t test
b
Exposed – unexposed adjusted for race, hypertensive pregnancy, and sex
ANCS-antenatal corticosteroid, hs-CRP- high sensitivity C- reactive protein, HbA1C-glycated hemoglobin
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Table 4
Anthropometrics at age 14 [mean ± SD or count (%)].
ANCS+
N=94
ANCS−
N=92 P value 
a
Adjusted Mean Differenceb,c [or Odds Ratio 
where noted] (95% CI)
P value
N=186
Height, cm 162.8 ± 8.7 159.7 ± 9.3 0.018 3.1 (0.7, 5.5)p=0.011
Weight, kg 58.8 ± 14.8 59.9 ±18.3 0.66 −1.2 (−6.2, 3.7)p=0.62
BMI, kg/m2 22.1 ± 5.0 23.3 ± 6.3 0.14 −1.2 (−3.0, 0.5)p=0.15
BMI ≥85th percentile 27 (29) 34 (37) 0.27 0.65 (0.34, 1.26)dP=0.20
Waist circumference, cm 78.0 ± 13.3 80.0 ± 16.7 0.40 −2.9 (−7.6, 1.8)p=0.23
Waist/height ratio 0.478 ± 0.079 0.500 ± 0.098 0.106 −0.030 (−0.058, −0.002)p=0.034
Triceps + subscapular skinfold thickness, 
mm
30.3 ± 16.7 35.2 ± 18.5 0.072 −4.8 (−10.1, 0.5)p=0.076
DXA n=92 n=81
Lean mass, kg 42.5 ± 9.8 42.5 ± 10.3 0.99 −0.1 (−2.8, 2.5)p=0.93
Lean mass index, kg/m2 15.9 ± 2.7 16.5 ± 2.9 0.18 −0.6 (−1.4, 0.2)p=0.15
Fat mass, kg 15.4 ± 8.7 17.0 ± 10.9 0.29 −1.8 (−4.8, 1.2)p=0.23
Fat mass index, kg/m2 5.9 ± 3.3 6.6 ± 4.1 0.18 −0.8 (−2.0, 0.2)p=0.13
aP value for comparison between ANCS groups based on two-sample t or Fisher exact test
b
Exposed–unexposed adjusted for race, hypertensive pregnancy, sex
cGeneral linear model least squares means
dOdds Ratio- adjusted for race and hypertensive pregnancy
ANCS-antenatal corticosteroid, BMI-body mass index, DXA- dual energy X-ray absorptiometry
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